* Note: Prices are in Million (M) USD.
Description:
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $97 M
Debt : $11 M
EBITDA : $28 M
Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 38.50
Since Forward PE Ratio is greater than 35, 0 point assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-29 M
Average Revenue: $57 M
Revenue Converted To Free Cash Flow (%): -51%
Avg Free Cash Flow Growth Per Year (Last 5 Years): 54.40%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $434 M
Revenue 4 Years Ago (2020-12-31): $29 M
Last 5 Years Average Revenue Growth: 284%
Since Revenue Growth is greater than 20, 5 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $65 M
Share Count 5 Years Ago (2020-12-31): $34 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $2.12
Trailing 12-Month Earnings Per Share (EPS): $0.79
Average Earnings Per Share (EPS): $1.46
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -69%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $56
52-Week Low: $33
Threshold Price (15% Above 52-Week Low): $37
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $3,418 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 16 points to above Protagonist Therapeutics Inc (PTGX) stock.
Last 1 Years Avg PE (Limited to last 1 years of EPS data) 9.19, Fair Value PE 20, Industry Based PE is 20 and Growth based PE is 40. Based on these all values average assigned is 22.30.
Value-Trades has assined P/E value 22.30. Since an average (Current Year EPS + Next Year EPS) earning per share is $1.46.
The fair value of Protagonist Therapeutics Inc (PTGX) stock should be (22.30 x $1.46) = $32.56
